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A case-matched study of stereotactic radiosurgery for patients 
with brain metastases: comparing treatment results for those  
with versus without neurological symptoms
Takao K iso1,2 · Masaaki Y mamoto1,3 · Takuya Kawabe4 · Shinya Wat nabe1,5 · 
Yasunori Sato6 · Yoshinori Higuchi7 · Tetsuya Yamamoto2 · Akira Matsumura2 · 
Hidetoshi Kasuya3 · Bierta E. Barfod1
bias in pre-SRS clinical factors between groups A and B, 
a case-matched study was conducted. Ultimately, 1644 
patients (822 in each group) were selected. The standard 
Kaplan–Meier method was used to determine post-SRS 
survival. Competing risk analysis was applied to estimate 
cumulative incidences of neurological death, neurological 
deterioration, local recurrence, re-SRS for new lesions and 
SRS-induced complications. Post-SRS median survival 
times (MSTs) did not differ between the two groups; 7.8 
months in group A versus 7.4 months in group B patients 
(HR 1.064, 95% CI 0.963–1.177, p = 0.22). However, 
cumulative incidences of neurological death (HR 1.637, 
95 % CI 1.174–2.281, p =0.0036) and neurological dete-
rioration (HR 1.425, 95 % CI 1.073–1.894, p = 0.014) were 
significantly lower in the group A than in the group B 
patients. Neurologically asymptomatic patients undergoing 
SRS for BM had better results than symptomatic patients 
in terms of both maintenance of good neurological state 
and prolonged neurological survival. Thus, we conclude 
that screening computed tomography/magnetic resonance 
imaging is highly beneficial for managing cancer patients.
Keywords Brain metastases · Radiation therapy · 
Radiosurgery · Gamma knife· Metastatic tumor
Introduction
Brain metastases (BMs) are generally a life-threatening 
neurological problem for cancer patients regardless of 
primary tumor sites [1–4]. However, due mainly to recent 
advances in systemic cancer treatment [5, 6], an appropri-
ately selected BM patient subgroup can now achieve longer 
surviv l with maintenance of good neurological function 
if BMs are well controlled. It is now widely recognized 
Abstract We aimed to reappraise whether post-stereotac-
tic radiosurgery (SRS) results for brain metastases differ 
between patients with and without neurologi al sym toms. 
This was an institutional review board-approved, retro-
spective cohort study using our prospec vely accumu-
lated database including 2825 consecutive BM patients
undergoing gamma knife SRS alone dur ng the 15-year 
period since July 1998. The 2825 patients were divided 
into two groups; neurologically asymptomatic [group A, 
1374 patients (48.6 %)] and neurologically symptomatic 
[group B, 1451 (51.4 %)]. Because there was considerable 
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function, meningeal dissemination, or an anticipated sur-
vival period of 3 months or less. As to tumor size, if MRI 
demonstrated tumors with diameters of 2–3 mm in the brain-
stem or the optic apparatus, we performed SRS rather than 
further follow-up observation. Otherwise, SRS was usually 
postponed with close MRI follow-up until the tumor diam-
eter exceeded approximately 1cm. Table 1 summarizes 
clinical characteristics, overall and for the two groups, i.e. 
neurologically asymptomatic (group A, 1374 patients) and 
symptomatic (group B, 1451 patients). As mentioned above, 
the primary physicians responsible for each patient decided 
the indications for both surgery and radiotherapy. Therefore, 
prior to SRS, among the 2825 patients, 523 (18.5 %) had 
undergone surgical removal of brain METs and 141 (4.8 %) 
WBRT (Table 1).
Before SRS, the treatment strategies were explained in 
detail to each patient, as well as at least one adult relative, 
and written informed consent was obtained from all patients 
before SRS by the second author (M.Y.). As our previous 
report described our radiosurgical techniques in detail, they 
are not repeated herein [22 , 23 ]. Briefly, standard SRS pro-
cedures were performed using a Leksell gamma unit Model 
B before June, 2003, and thereafter a Leksell gamma unit 
Model C (Elekta AB, Stockholm, Sweden).
Post-SRS, all patients were routinely managed by refer-
ring physicians and were recommended to have clinical and 
neuro-imaging examinations at an approximately 2–3 month 
interval. Neuroimaging follow-up could not be performed 
in 815 patients (28.9 %); mostly because of post-SRS early 
deterioration due to systemic diseases [median survival time 
of this subset was 2.5 (95 % CI 2.3–2.6 months)]. Approx-
imately 50 % of our 2825 patients came to our outpatient 
clinic periodically, while clinical and/or neuroimaging data 
were sent to us by post in about 25% of cases. The second 
author (M.Y.) called the remaining 25 % of patients or their 
relatives by telephone to confirm the patients’ conditions. 
For deceased patients, the day of death, cause of death, and 
detailed information on patient condition changes were 
requested by telephone.
Clinical outcomes
As clinical outcomes were described in detail in our previ-
ous report, they are not repeated herein [22 , 23 ]. Briefly, the 
primary endpoint was overall survival, and the secondary 
endpoints were neurological death, neurological deteriora-
tion, local recurrence of the treated tumor, repeat SRS for 
new lesions, salvage WBRT, salvage surgery, and SRS-
induced major complications. For each endpoint, failures 
were regarded as events and any others as censored. Overall 
survival time was defined as the interval between the first 
SRS and death due to any cause (progression of systemic 
metastases and/or BM, other disease unrelated to cancer, 
that not only prolonged survival but also m intenance of 
good neurological function s crucial for managing patients 
with BMs. Thus, successful management requires precis
BM diagnosis in an early disease stag , i.e., before a BM 
manifests with neurological symptoms. Figlin et al. rep rted 
BM to be discovered within 2 years after initial treatment 
of lung cancer [7]. Mor over, with wid sp ead use of com-
puted tomography (CT) and/or magnetic resonance images 
(MRI), increasing numbers of patients with asymptomatic 
BMs are being diagnosed [5, 6, 8–10]. Most notably, MRI is 
more sensitive than CT for BM detection [5,10–14]. BMs 
were reportedly found in 6–30 % of initially-d agnosed 
lung cancer patients [6, 10, 15 –19] a d were neu ologically
silent in 14 % [5].
As Lippitz et al. recently reviewed xtensively, stereotac-
tic radiosurgery (SRS) has become an establish d treatment 
option for managing BM patients [20]. SRS is more dvan-
tageous than other treatments, i.e., whole b ain radiother py 
(WBRT), surgery, systemic anti-cancer agen  therapy and 
combinations of these modalities, in terms of costs, hosp-
talization, morbidity, mort lity and wide  applicability and 
repeatability [21 ]. W h all cancer tr atm nt modalities, it 
is generally believed that both early diagnosis and immedi-
ate treatment improve patient outcomes. Although consider-
able numbers of series, both prospective and re rospective, 
have demonstrated treatment results including neurologi-
cal survival and maintenanc  of neurologic l condition in 
BM patients undergoing SRS, li tle is known about whether 
post-SRS results for BM differ between patients with and
without neurological symptoms. We imed to reappraise 
whether neurologically-asymptomatic pa ients are more
likely to benefit from SRS, in terms of both neurological 
survival and maintenance of neurolog cal condition, than 
symptomatic patients.
Materials and methods
Patient population
This was an institutional review b ard (IRB)-approved, 
retrospective cohort study using our prospectively accu-
mulated database including 2825 co secutive BM pati nts 
undergoing gamma knife SRS alone during the 15-y ar
period between July 1998 and June 2013 (Tokyo Women’
Medical University IRB: #1981). As all pati nts had been 
referred to us for SRS, their primary physicia s had mostly 
made the patient selections. Patient election criteri  m y 
thus have differed among referring physi ians. Therefore, 
one author (MY) decided wheth  o  not to accept a patient. 
We did not perform SRS on patients with low Karnofsky 
Performance Status (KPS) scores (<70 %) due to sy temic 
diseases, a non-cooperative s te due to po neurocognitive 
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Characteristics Total Neurological symptoms p 
valuesa
No (group A) Yes (group B)
No. of patients 2825 1374 1451
Age (years)
Mean 64 64 65 0.05
Range 19–96 19–96 19–93
Sex
Female 1134 (40.1 %) 547 (39.8 %) 587 (40.5 %) 0.73
Tumor numbers
Mean 7 7 7 0.45
Median 3 3 3
Range 1–89 1–69 1–89
IQR 1–8 1–8 1–8
Primary cancer sites
Lung 1840 (65.1 %) 1046 (76.1 %) 794 (54.7 %) <0.001b
Breast 309 (10.9 %) 122 (8.9 %) 187 (12.9 %)
GI tract 328 (11.6 %) 87 (6.3 %) 241 (6.9 %)
Kidney 115 (4.1 %) 47 (3.4 %) 68 (3.3 %)
Others 233 (5.7 %) 72 (5.2 %) 161 (11.1 %)
Primary cancer status
Controlled 865 (30.7 %) 414 (30.1 %) 451 (31.1 %) 0.60
Extra-cerebral METs
No 1456 (51.5 %) 695 (50.6 %) 679 (49.4 %) 0.33
KPS
≥80 % 2150 (76.1 %) 1176 (85.6 %) 974 (67.1 %) <0.001
Modified-RPA class [34, 35]
1 + 2a 638 (22.6 %) 363 (26.4 %) 275 (19.0 %)
2b 872 (30.9 %) 457 (33.3 %) 415 (28.6 %) 0.08c
2c + 3 1315 (46.5 %) 554 (40.3 %) 761 (52.5 %) <0.001d
Prior surgery
Yes 523 (18.5 %) 113 (8.2 %) 410 (28.3 %) <0.001
Prior WBRT
Yes 141 (5.0 %) 85 (6.2 %) 56 (3.9 %) 0.006
Tumor volume (cc)
Cumulative
Mean 9.74 6.43 12.87 <0.001
Range 0.01–126.2 0.01–115.3 0.04–126.2
IQR 1.89–12.92 0.89–8.21 3.69–17.45
Largest tumor
Mean 6.78 4.42 9.02 <0.001
Range 0.01–94.20 0.01–94.20 0.02–89.30
IQR 1.10–8.81 0.52–5.22 2.60–11.80
Peripheral dose (Gy)
Mean 21.12 22.01 20.52 <0.001
Range 10.00–32.00 12.00–32.00 10.00–25.00
IQR 20.00–24.00 20.00–24.00 18.00–24.00
IQR interquartile range, GI gast ointestinal, METs metastases, KPS Karnofsky Performance Status,12RPA re ursive partitioning analysis, 
4WBRT whole brain radiotherapy, CI confi ence interval
aStudent t test was used for continuous variables and Fisher’s exact test for pairs of categorical variables, bLung versu  non-lung, cModified-RPA 
classes 1 + 2a versus 2b, dModified-RPA classes 2b versus 2c + 3
Table 1 Summary of clinical characteristics of 2825 brain metastasis patients (cohort)
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statistician (YS) using SAS software version 9.4 (SAS Insti-
tute, Cary, NC, USA) and the R statistical program, version 
3.10. Before statistical analyses, the database was cleaned 
(by YH). These two authors were not involved in either SRS 
treatment or patient follow-up.
Results
Cohort studies
Four patients were lost to follow-up (0.34%, three in group 
A and one in group B). As of January 2014, the median 
post-SRS observation time among censored observations 
(212 patients) was 41.9 (IQR 8.7–54.0, maximum 173.5) 
months and 2609 patients (92.4 %) had died. The overall 
median survival time (MST) after SRS was 7.6 months 
(95 % CI 7.3–8.0 months). Actuarial post-SRS survival rates 
accident, suicide, and so on) or the day of the last follow-up. 
Neurological death was defined as death caused by any intra-
cranial disease, including tumor recurrence, carci omatous
meningitis, cerebral dissemination, and pr gression of other 
untreated intracranial tumors. Neurological deterioration-
free survival time was defined as the interval between the 
first SRS and the day that any brain disease-caused neuro-
logical worsening manifested (that is, local recurrence, pro-
gression of new lesions, and SRS-induced complications). 
Decreases in KPS scores, in patien s with cores of 20 % or 
less, due to neurological worsening were regarded as events 
and any others as censored. Major complication-free sur-
vival time was taken as the interval between the first SRS 
and the day major SRS-induced complications ccurr d. 
Patients with major complications included those with 
Radiation Therapy Oncology Group (RTOG) neurotoxic-
ity grades of 2 or worse and, eve if the grade was either 
0 or 1, those in whom surgical intervention was requ red 
based on sequential MRI follow-up demonstrating progres-
sive enlargement of a cyst and/or a mass lesion with further 
observation thus being regarded as excessively high risk; all 
of these conditions were regarded as events and any others 
as censored [24].
Statistical analysis
All data were analyzed according to the intention-to-treat 
principle. For baseline variables, summary statistics were 
constructed using frequencies and proportions for categori-
cal data and medians, ranges and interquartile ranges (IQR) 
for continuous variables. We compared patient characteris-
tics using the Fisher exact test for categorical outcomes and 
t-tests for continuous variables, as appropriate. The Kaplan–
Meier method was used to estimate overall survival. More-
over, univariate analysis using the Cox proportional hazard 
model was performed to determine pre-SRS clinical factors 
favoring longer survival.
For time-to-event outcomes, the cumulative incidences 
of neurological death, neurological deterioration, local 
recurrence, repeat SRS, and major complications were esti-
mated by a competing risk analysis, because death is a com-
peting risk for loss to follow-up (that is, patients who die 
can no longer become lost to follow-up) [25–27]. Also, to 
identify baseline and clinical variables associated with the 
5 aforementioned outcomes, competing risk analyses were 
performed with the Fine–Gray generalization of the propor-
tional hazards model accounting for death as a competing 
risk [28 ]. Fine–Gray generalization makes use of the sub-
distribution hazard to model cumulative incidence, thereby 
quantifying the overall benefit or harm of an exposure [29].
All comparisons were planned and the tests were two-
sided. A p value of <0.05 was considered to be statistically 
significant. All statistical analyses were performed by a 
Fig. 1 Overall survival based on 2825 patients () and on a subset 
of 1644 case-matched patients (b) accord ng to neurological symp-
toms [asymptomatic (group A) and symptomatic (group B)], estimated 
using the standard Kaplan–Meier method
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Characteristics Total Neurological symptoms p 
valuesa
No (group A) Yes (group B)
No. of patients 1644 822 822
Age (years)
Mean 64 64 65 0.04
Range 19–96 19–96 19–93
Sex
Female 650 (39.5 %) 327 (39.8 %) 323 (39.3 %) 0.88
Tumor numbers
Mean 7 8 7 0.87
Median 3 4 3
Range 1–89 1–63 1–74
IQR 1–9 1–9 1–8
Primary cancer sites
Lung 1077 (65.5 %) 531 (64.6 %) 546 (66.4 %) 0.47a
Breast 192 (11.7 %) 101 (12.3 %) 91 (11.1 %)
GI tract 172 (10.5 %) 87 (10.6 %) 85 (10.3 %)
Kidney 79 (4.8 %) 42 (5.1 %) 37 (4.5 %)
Others 124 (7.5 %) 61 (7.4 %) 63 (7.7 %)
Primary cancer status
Controlled 507 (30.8 %) 254 (30.9 %) 253 (30.8 %) 1.00
Extra-cerebral METs
No 830 (50.5 %) 412 (50.1 %) 418 (50.9 %) 0.81
KPS
≥80 % 1291 (78.5 %) 647 (78.7 %) 644 (78.4 %) 0.90
Modified-RPA class [34, 35]
1 + 2a 354 (21.5 %) 172 (20.9 %) 182 (22.1 %)
2b 528 (32.1 %) 272 (33.1 %) 256 (31.1 %) 0.41c
2c + 3 762 (46.4 %) 378 (46.0 %) 384 (46.7 %) 0.53d
Prior surgery
Yes 231 (14.1 %) 113 (13.8 %) 118 (14.4 %) 0.78
Prior WBRT
Yes 75 (4.6 %) 36 (4.4 %) 39 (4.7 %) 0.81
Tumor volume (cc)
Cumulative
Mean 8.92 8.80 9.04 0.87
Range 0.01–115.3 0.01–115.3 0.05–77.88
IQR 2.18–11.74 1.80-11.66 2.62–11.95
Largest tumor
Mean 6.17 6.06 6.29 0.65
Range 0.02–94.20 0.02–94.20 0.05-70.00
IQR 1.31–7.80 0.92–7.82 1.80–7.80
Peripheral dose (Gy)
Mean 21.32 22.28 21.30 0.55
Range 10.00–25.00 12.00–32.00 12.00–25.00
IQR 20.00–24.00 20.00–24.00 20.00–24.00
IQR interquartile range, GI gast ointestinal, METs metastases, KPS Karnofsky Performance Status,12RPA re ursive partitioning analysis, 
4WBRT whole brain radiotherapy, CI confi ence interval
aStudent t test was used for continuous variables and Fisher’s exact test for pairs of categorical variables, bLung versu  non-lung, cModified-RPA 
classes 1 + 2a versus 2b, dModified-RPA classes 2b versus 2c + 3
Table 2 Summary of clinical characteristics of 1644 case-matched brain metastasis patients
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tumor sites, Karnofsky score, Modified-Recursive Partition-
ing Analysis classes, prior procedures [surgery and WBRT], 
cumulative tumor volume, volume of the largest tumor, 
and peripheral doses), all of which had p values <0.05 [31 , 
32 ]. After all of the propensity-score matches had been per-
formed, we compared baseline characteristics between the 
two groups. Ultimately, 1644 patients (822 in each group) 
were selected. The p values after matching were over 0.05 
for all clinical factors except age (Table 2). H wev r, the 
difference in mean ages was only 1.2 years (63.8 years/
group A vs. 65.0 years/group B). This difference is not con-
sidered to be clinically meaningful.
As shown in Fig.1 , although the post-SRS MST was 
slightly longer in group A (7.8 months) than in group B 
(7.4 months) patients, this difference was not statistically 
significant (HR 1.064, 95 % CI 0.963–1.177, p = 0.22). 
Both crude and cumulative incidences of neurological 
death were significantly lower in group A than in the group 
B patients (HR 1.637, 95 % CI 1.174–2.281, p = 0.0036) 
(Tables 3, 4). Although crude incidences of neurologi-
cal deterioration did not differ significantly between the 
two patient groups, cumulative incidences of neurological 
deterioration were significantly lower in the group A than 
in the group B patients (HR 1.425, 95 % CI 1.073–1.894, 
p = 0.014).
Crude and cumulative incidences of local recurrence, 
repeat-SRS and SRS-related complications did not differ 
significantly between the two patient groups, as shown in 
Tables 3 and 4. Also, the crude incidence of salvage treat-
ment, i.e., surgery or WBRT, did not differ significantly 
between the two patient groups (Table 3).
Four major original cancers
There were no significant MST differences between the 
two groups, A and B, in patients with lung, gastro-intestinal 
and renal cancers (Table 3). However, in those with breast 
cancer, the MST of the group A patients [12.3 (95 % CI 
8.7–16.0) months] was significantly longer than that of the 
group B patients [8.3 (6.4–10.8) months, p =0.01]. In lu g 
cancer patients, the crude incidence of neurological death 
was significantly higher in the group B patients (12.8 %) 
than in the group A patients (8.1 %, p =0.02). However, 
there were no significant differences in the incidence of 
neurological death between the A and B groups for patients 
with breast, gastro-intestinal and renal cancers. Also, in 
lung cancer patients, the crude incidence of neurological 
deterioration in the group B patients (15.2 %) was signifi-
cantly higher than that in the group A patients (10.0 %, 
p = 0.01). There were, however, no significant differences 
in the incidence of neurological deterioration between 
groups A and B for patients with breast, gastro-intestinal 
and renal cancers.
were 58.6, 34.3, 15.4, 8.6, and 4.7 % at the 6th, 12th, 24th, 
36th, and 60th post-SRS month, esp ctive y. Among the
2609 deceased patients, causes of death could not be deter-
mined in 109, but were confirmed in the remaining 2500 
to be non-brain disease in 2211 (88.4 %) and brain dis ase 
in 289 (11.6 %). MST after SRS was significantly longer 
in the 1374 group A (8.9 months) th n in he 1451 g oup 
B (6.7 months) patients (HR 1.238, 95 % CI 1.146–1.337
p < 0.001) (Fig. 1).
Among 1840 patients with lung cancer, BMs had not 
manifested with neurological symptoms at the time of SRS 
in 1046 (56.9 %)  However, 39.5 % (122/309 patients) of 
breast cancer, 26.5 % (87/328) of gastro-intestinal tract can-
cer and 40.9 % (47/115) of renal cancer patients underw nt 
SRS for asymptomatic BMs.
Studies of case-matched subset
As shown in Table 1, proportions of patients with some of 
the clinical characteristics differed significantly between 
groups A and B, i.e., proportions of pr mary cancer sites, 
KPS, Modified-RPA classes, and prior treatments (surgery 
and WBRT) were strikingly unev n and both cumulative 
tumor volumes and the volum s of the largest tumors dif-
fered significantly between the two groups. These differ-
ences might have impacted s rvival and/or neurologi al 
deterioration. Therefore, a case-matched tudy was con-
ducted by one of the authors (Y.S.), w o did no  partici-
pate in other aspects of this study and was blinded to final 
outcomes. Patient selection was perform d employing the 
propensity score matching method with a Greedy 5-To-1 
Digit-Matching algorithm [30] for clinical factors (primary 
Table 3 Summary of treatment results af er stereotactic radiosurgery 
(SRS)
Neurological symptomsp 
value
No (group A)Yes (group B)
No. of patients822 822
Neurological deatha 58 (7.9 %) 88 (11.9 %) 0.01
Neurological deterioration84 (10.2 %) 110 (13.4 %) 0.06
Local recurrenceb 48 (8.5 %) 57 (9.5 %) 0.54
Repeat SRS 259 (31.5 %) 224 (27.3 %) 0.07
Salvage WBRT 36 (4.4 %) 23 (2.8 %) 0.11
Salvage surgery14 (1.7 %) 15 (1.8 %) 1.00
SRS-related complications30 (3.7 %) 24 (2.9 %) 0.49
aBased on 1471 [734 (96.0 %) in group A and 737 (96.6%) in group B, 
p = 0.59] deceased patients whose causes of death were determined 
(57 patients were excluded becau e c uses of death were not avail-
able)
bBased on 1165 [567 (69.0 %) in group A and 598 (72.8%) in group B, 
p = 0.10] patients (479 patients were excluded because neuro-imaging 
results were not available)
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In general, earlier diagnosis and non-delayed treatment 
are believed to improve treatment outcomes for patients 
with all types of malignant tumors. However, based on 181 
patients, Seute et al. reported chemotherapies to be inef-
fective for asymptomatic BM from small cell lung cancer 
[17 ]. Kim et al. also reported that there was no significant 
difference in overall survivals between 7 asymptomatic and 
31 symptomatic patients with BM from non small cell lung 
cancer (NSCLC) (43 vs. 45 weeks, p = 0.3689) [6]. Kuba 
et al. obtained similar results in 53 asymptomatic and 12 
symptomatic patients with BM from breast cancer (12 vs. 13 
months, p = 0.99) [37]. Brain CT for lung cancer patients is 
recommended only for those who are neurologically symp-
tomatic, because screening neuro-imaging examinations are 
not cost-effective for asymptomatic patients [38 , 39]. We 
disagree with this view. We advocate considering that once 
a cancer patient becomes neurologically-handicapped, med-
ical costs far exceed that for a single neuro-imaging exami-
nation using either CT or MRI, though it must be noted that 
these costs vary markedly among countries, i.e., approxi-
mately US$300 in Japan, even if a contrast study is added, 
Discussion
Debate continues as to whether post-treatment survival peri-
ods are significantly longer in neurologically asymptom-
atic patients than in symptomatic patients. Neurologically 
asymptomatic patients reportedly have be t r outcomes [2, 
33–36], though some authors have a gued against such a 
relationship [6, 17 , 37]. However, all previously reported 
series were based on relatively small sample siz s. Further-
more, only overall survivals were discussed n prio  reports, 
with neithor neurological urvival nor maintenance of neu-
rological condition being described. Maintenance of good 
neurological function and, eventually, a decreased incidence 
of neurological death, have recently been recog zed as 
being crucial for managing patients with BMs. We consider 
our herein-reported dataset, with a relatively large s mple 
size, to show that SRS, prior to BMs becoming neurologi-
cally symptomatic, has the potential to achi ve prolonged 
maintenance of neurological function and o minimize neu-
rological death, although MST did not differ significantly 
between the two groups.
Cumulative incidences (post-SRS months)HR (95 % CI) p 
value
6 12 24 36
Neurological death 1.637 (1.174–2.281) 0.0036
Asymptomatic (group 
A)
0.021 0.033 0.057 0.068
Symptomatic (group 
B)
0.030 0.073 0.100 0.110
Neurological 
deterioration
1.425 (1.073–1.894)0.014
Asymptomatic (group 
A)
0.032 0.057 0.080 0.096
Symptomatic (group 
B)
0.047 0.093 0.121 0.130
Local recurrencea 1.360 (0.926–1.998)0.11
Asymptomatic (group 
A)
0.017 0.046 0.062 0.072
Symptomatic (group 
B)
0.023 0.057 0.091 0.099
Repeat SRS 0.880 (0.736–1.053)0.16
Asymptomatic (group 
A)
0.153 0.256 0.301 0.318
Symptomatic (group 
B)
0.131 0.229 0.269 0.275
SRS-related 
complications
0.088 (0.514–1.507)0.64
Asymptomatic (group 
A)
0.006 0.013 0.021 0.026
Symptomatic (group 
B)
0.012 0.021 0.027 0.027
SRS stereotactic radiosurgery, HR hazard ratio, CI confidence interval
aBased on 1165 [567 (69.0 %) in group A and 598 (72.8 %) in group B, p = 0.10] patients (479 patients were 
excluded because neuro-imaging results were not available)
Table 4 Summary of time-to-
event outcome studies using 
competing risk analyses
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and colleagues reported that, based on 1196 prospectively 
enrolled patients undergoing gamma knife SRS, there were 
significant MST differences in Mets between asymptom-
atic and symptomatic patient groups (HR 1.779, 95 % CI 
1.541–1.589, p< 0.0001) [35]. However, in both reports, 
there were considerable biases between the asymptomatic 
and symptomatic patient groups, i.e., the tumor volume was 
larger and KPS scores were lower in the symptomatic than 
in the asymptomatic group [34].
The major weakness of the present study is that it was 
retrospective. As we discussed in our previous articles, the 
characteristics of patients receiving a particular treatment 
regimen are considered to have a major influence on treat-
ment selection. This is an important issue when estimating 
the effects of treatments or exposures on outcomes using 
observational data. One approach to reducing or eliminat-
ing the effect of treatment selection bias and confounding 
effects is to use propensity score matching, which allows 
one to design and analyze an observational (non-random-
ized) study that mimics some of the characteristics of a 
randomized controlled trial. Therefore, in the present inves-
tigation, a case-matched study was also conducted by one of 
the authors (Y.S.), who did not participate in other aspects of 
this study and was blinded to final outcomes. Nevertheless, 
because this was a retrospective study, even with the appli-
cation of case matching, biases in patient selection, original 
cancer treatments over time, follow-up (outcome, toxicity, 
and imaging), observers, and so on, could not be eliminated.
The other weakness of this study is the lack of informa-
tion on tumor locations. It is absolutely crucial to describe 
tumor location when neurological symptoms are discussed. 
However, unfortunately, our retrospectively-accumulated 
database did not include information on tumor locations and, 
therefore, we could not examine the impact of this factor.
Moreover, there are several differences in welfare and 
health insurance systems between Japan and other coun-
tries, and these have major impacts on the cost of screening 
examinations such as MRI. Factoring in quality-adjusted 
life years for patients receiving versus not receiving routine 
scanning would be useful.
and US$3000 in the USA. Moreover, expenses are not he 
only consideration. The difficulty and anxiety experienced 
by neurologically-handicapped patient  mu t also be taken 
into account. In fact, most physicians in Japan are now per-
forming screening MRI for lung cancer patients, ven those 
who are neurologically asymptomatic, as described above. 
We advocate that this policy be generally adopt d by phy i-
cians who manage cancer patients, regardless of the original 
tumor type.
However, it should be kept in mind that BMs occur at 
a relatively early disease s age in lung cancer patients as 
compared to those with breast, gastro-intestinal tract o  kid-
ney cancers, as shown in Table 5 (on line only). This issue
makes it difficult to perform screening MR imaging exami-
nations for all patients with non-lung cancers. I  fact, the 
high costs of neuro-imaging examinations re considered 
to be a major hurdle to routinely using CT/MRI for cancer 
patients without neurological symptoms in the USA. Never-
theless, as described above, SRS for non-symptom tic BMs 
was clearly shown to have survival benefits in breast can-
cer patients. As with lung c cer patients, we recommend 
screening neuro-imaging examinations for breast cancer
patients at high risk for BMs, i.e., as reported by Barnh ltz-
Sloan et al. and Shouteen et al. ho fou d incidences of 
BMs to be higher in patients with advanced disease [40, 
41]. In this study, we found that performing SRS for non-
symptomatic BMs in patients with gastro-i estinal and
renal cancers provided no benefits in terms of neurological 
death or maintenance of neurological condition. For the e 
patients, periodic CT examinations for re-staging consis-
tently including the brain are worthwhile for detecting BM 
before they manifest with neurological symptoms.
In contrast, Sanchez et al. found neurol gically asymp-
tomatic NSCLC patients to have longer surviva ; the MST 
of 12 asymptomatic patients was 7.5 months and that of 69 
symptomatic patients was 4.0 mon s (p = 0.02) [34]. More-
over, they also reported that control of t e neurological 
status of asymptomatic patients is better t an that of symp-
tomatic patients (80 vs. 40 %) [34]. However, these reports 
described a small number of p tie ts. Yamamoto, Serizawa, 
Table 5 Number of patients with synchronous versus metachronous presentation and interval between diagnosis of primary cancer and stereotac-
tic radiosurgery (SRS) (cohort)
Primary cancer sitesNo. of patientsPresentation Interval (months) between diagnosis of 
primary cancer and SRS
SynchronousMetachronousMean/median Maximum/IQR
Lung 1840 378 (20.5 %) 1462 (79.5 %) 17/10 262/3–21
Breast 309 4 (1.3 %) 305 (98.7 %) 59/48 289/27–78
GI tract 328 25 (7.6 %) 303 (92.4 %) 34/24 237/11–45
Kidney 115 10 (8.7 %) 105 (91.3 %) 55/29 324/8–90
GI gastro-intestinal
p < 0.0001
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 9. Shi AA, Digumarthy SR, Temel JS et al (2006) Does initial stag-
ing or tumor histology better identify asymptomatic brain metas-
tases in patients with non-small cell lung cancer? J Thorac Oncol 
1:205–210
10. Yokoi K, Kamiya N, Matsuguma H et al (1999) Detection of 
brain metastasis in potentially operable non-small cell lung can-
cer: a comparison of CT and MRI. Chest 115:714–719
11. Davis PC, Hudgins PA, Peterman SB et al (1991) Diagnosis 
of cerebral metastases: double-dose delayed CT vs contrast-
enhanced MR imaging. Am J Neuroradiol 12:293–300
12. Lemiere C, Peretti-Viton P, Thomas P et al (1995) Spreading eval-
uation in primitive bronchogenic carcinoma: benefit of cerebral 
MRI compared to CT scan. Eur J Cancer 31 A:1715
13. Sze G, Milano E, Johnson C et al (1990) Detection of brain 
metastases: comparison of contrast-enhanced MR with unen-
hanced MR and enhanced CT. Am J Neuroradiol 11:785–791
14. Yuh WT, Fisher DJ, Runge VM et al (1994) Phase III multicenter 
trial of high-dose gadoteridol in MR evaluation of brain metasta-
ses. Am J Neuroradiol 15:1037–1051
15. Cox JD, Yesner RA (1979) Adenocarcinoma of the lung: recent 
results from the Veterans Administration Lung Group. Am Rev 
Respir Dis 120:1025–1029
16. Newman SJ, Hansen HH (1974) Proceedings: frequency, diagno-
sis, and treatment of brain metastases in 247 consecutive patients 
with bronchogenic carcinoma. Cancer 33:492–496
17. Seute T, Leffers P, ten Velde GP et al (2004) Neurologic disorders 
in 432 consecutive patients with small cell lung carcinoma. Can-
cer 100:801–806
18. Sorensen JB, Hansen HH, Hansen M et al (1988) Brain metas-
tases in adenocarcinoma of the lung: frequency, risk groups, and 
prognosis. J Clin Oncol 6:1474–1480
19. Vines EF, Le Pechoux C, Arriagada R (2003) Prophylactic cranial 
irradiation in small cell lung cancer. Semin Oncol 30:38–46
20. Lippitz B, Lindquist C, Paddick I et al (2014) Stereotactic radio-
surgery in treatment of brain metastases: the current evidence. 
Cancer Treat Rev 40:48–86
21. McDermott MW, Sneed PK (2005) Radiosurgery in metastatic 
brain cancer. Neurosurgery 57(Suppl S4):45–53
22. Yamamoto M, Kawabe T, Higuchi Y et al (2012) Validity of three 
recently proposed prognostic grading indexes for breast cancer 
patients with radiosurgically treated brain metastases. Int J Radiat 
Oncol Biol Phys 84:1110–1115
23. Yamamoto M, Kawabe T, Sato Y et al (2013) A case-matched 
study of stereotactic radiosurgery for patients with multiple brain 
metastases: comparing treatment results for 1–4 vs ≥ 5 tu ors:
clinical article. J Neurosurg 118:1258–1268
24. Radiation Therapy Oncology Group (2015) Cooperative group 
common toxicity criteria. (ht ps://www.rtog.org/ResearchAssoci-
ates/AdverseEventReporting/CooperativeGroupCommonToxici-
tyCriteria.aspx). Acce sed 1 Sep 2015
25. Gooley TA, Leisenring W, Crowley J et al (1999) Estimation of 
failure probabilities in the presence of competing risks: new rep-
resentations of old estimators. Stat Med 18:695–706
26. Gray RJ (1988) A class of K-sample tests for comparing the cumu-
lative incidence of a competing risk. Ann Stat 16:1141–1154
27. Satagopan JM, Ben-Porat L, Berwick M et al (2004) A note 
on competing risks in survival data analysis. Br J Cancer 
91:1229–1235
28. Fine JP, Gray RJ (1999) A: proportional hazards model for the 
subdistribution of a competing risk. J Am Stat Assoc 94:496–509
29. Bakoyannis G, Touloumi G (2012) Practical methods for compet-
ing risks data: a review. Stat Methods Med Res 21:257–272
30. Parsons LS (2015) Reducing bias in a propensity score matched-
pair sample using greedy matching techniques. SAS. http://
www2.sas.com/proceedings/sugi26/p214-26.pdf. (Accessed  
Sep 2015)
A randomized controlled trial, in the near futur , is nec-
essary to test the hypothesis put forth herein.
Conclusion
Neurologically asymptomatic pati nts who und rwent 
SRS for BM had better results t  symptomatic patients 
in terms of maintenance of a good neurological state and a 
reduction in the neurological death rate. Our results indicate 
that screening for BM by CT/MRI may be beneficial for 
managing cancer patients. These obs rvations merit further 
detailed research.
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